BioFlorida retweeted
Alzheimer's Association
@alzassociation
22 Dec 2023
Tonight on the winter solstice, #TheLongestDay participants across the country will display luminaries 🕯️ in windows and doorsteps to raise Alzheimer's awareness. We thank all of them for sharing why they're fighting to #ENDALZ. #WinterSolstice.
0
9
51
3,721
BioFlorida@BioFlorida
22 Dec 2023
MEMBER NEWS: @AdmaBiologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older. View full news release: ir.admabiologics.com/news-releases/…
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced the U.S. Food and Drug Administration (“FDA”) has approved the Company’s supplemental Biologics License Application submitted under section 351(a) of the Public Health Service Act for BIVIGAM. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment. Additionally, the approval provides for a revision of BIVIGAM’s prescribing information to expand the primary humoral immunodeficiency (“PI”) indication to pediatric patients 2 years of age and older.
0
0
1
254
BioFlorida retweeted
Cyclo Therapeutics, Inc.@Cyclodexpert
18 Dec 2023
The FDA feedback we received allows us to proceed as planned to bring a potential treatment option to this underserved patient community.

bit.ly/3NsbJFZ
$CYTH #NiemannPick #NPC1
0
1
7
440
BioFlorida@BioFlorida
20 Dec 2023
MEMBER NEWS: @ZyVersaThera Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200. View full news release: investors.zyversa.com/news-releases/…
WESTON, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces selection of contract research organization (“CRO”) George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD). The clinical trial is expected to begin in the first quarter of 2024.
0
0
0
195
BioFlorida retweeted
Arthrex
@Arthrex
11 Dec 2023
Future innovators found a home at #Arthrex this weekend!

We were proud to host a robotics competition for @FTCTeams (part of the global nonprofit @FIRSTweets). Students worked in teams to design, build and code robots, developing STEM skills and learning engineering principles.
0
2
4
621
BioFlorida@BioFlorida
12 Dec 2023
MEMBER NEWS: The University of Florida, Concept Companies, and Trimark Properties Join Forces To Make Gainesville's Innovation District a Major Economic Hub. Read the news: innovate.research.ufl.edu/2023/12/08/uf-…
0
0
0
126
BioFlorida retweeted
Moffitt Cancer Center
@MoffittNews
11 Dec 2023
Live from #ASH23: Drs. @Ramikomrokji and Jeffrey Lancet discuss the emerging clinical evidence in the treatment and management of myelodysplastic syndrome. #MoffittASH23
0
7
20
2,013
BioFlorida retweeted
Globant
@Globant
11 Dec 2023
Over the last 20 years, we've contributed to talent development, entrepreneurship, and communities.

Take a look at our Impact Report.
👉 globant.link/41f0A17

#Globant20 #GlobantImpact
0
12
34
4,591
BioFlorida retweeted
Dr. Patrick Hwu
@PatrickHwuMD
11 Dec 2023
In a new study published in @NatureComms, @MoffittNews researchers report on the identification of a cell signaling pathway that regulates the metastatic spread of #melanoma cells to the brain. @LabSmalley
moffitt.org/newsroom/news-…
1
7
21
2,403
BioFlorida retweeted
Gift of Life@GiftofLife
11 Dec 2023
Idan is our little hero who faced a rare immune disorder at eight months old.

🦸‍♂️ Thanks to Alex, who donated his blood stem cells, Idan is now thriving!

⌛Help us create more stories like Idan's—donate on our website: bit.ly/3GqPzAh

#CureBloodCancer #SavingLives
0
1
3
154
BioFlorida retweeted
NeoGenomics@NeoGenomics
11 Dec 2023
(1/2) NeoGenomics is thrilled to announce a recently published paper in Clinical Cancer Research highlighting our MultiOmyx™ technology. Our colleague Qingyan 'Sandy' Au PhD and collaborator Ken Young, MD, Duke University Medical Center co-presented at the American Society of
1
1
1
218
BioFlorida@BioFlorida
11 Dec 2023
MEMBER NEWS: The University of Florida, Concept Companies, and Trimark Properties Join Forces To Make Gainesville's Innovation District a Major Economic Hub. Read news: innovate.research.ufl.edu/2023/12/08/uf-… @UF @UFInnovate
The University of Florida Board of Trustees was briefed today on a new plan to join Concept Companies and Trimark Properties in developing roughly 13 acres east of campus into a world-class destination for Fortune 500 research companies and creating a talent pipeline for UF students seeking high-paying jobs. This strategic collaboration will further advance Gainesville’s Innovation District and bring it closer to achieving its identity as a bastion of progress.
0
0
1
103
BioFlorida@BioFlorida
11 Dec 2023
This Thursday! Reg today: bioflorida.com/events/EventDe…
0
0
0
75
BioFlorida retweeted
Palm Beach State College@PBStateCollege
9 Dec 2023
Reminder: Spring 2024 term starts Mon., Jan. 8, 2024. Register today to secure your classes now. Share this with someone who could use a reminder.
palmbeachstate.edu/getstarted/def…

#MyPBSC
0
2
6
281
BioFlorida retweeted
NeoGenomics@NeoGenomics
9 Dec 2023
Join NeoGenomics at #ASH23, booth #851, to uncover the latest breakthroughs shaping the future of heme oncology testing.

#NeoGenomics #ASH23
0
1
2
152
BioFlorida retweeted
NeoGenomics@NeoGenomics
8 Dec 2023
Learn more about our oral and poster presentations at #ASH23.
NeoGenomics: Leading the way in heme cancer testing with groundbreaking insights.
#ASH23 #Hematology #NeoGenomics #HemeCancers
0
2
2
182
BioFlorida@BioFlorida
7 Dec 2023
MEMBER NEWS: ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering. View full news release: investors.zyversa.com/news-releases/… @ZyVersaThera
WESTON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases with high unmet needs, announced today the pricing of a “reasonable best efforts” public offering of 4,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A and Series B warrants to purchase up to an aggregate of 8,000,000 shares of common stock at a combined public offering price of $1.25, resulting in gross proceeds of approximately $5.0 million. The Series A Warrants to purchase up to an aggregate of 4,000,000 shares of common stock and Series B Warrants to purchase up to an aggregate of 4,000,000 shares of common stock will have an exercise price of $1.25 per share, will be exercisable immediately following the date of issuance and will expire five years and eighteen months from the orig
0
0
0
43
BioFlorida retweeted
Dr. Patrick Hwu
@PatrickHwuMD
7 Dec 2023
Had a jolly good time bringing holiday cheer to team members, patients and friends @MoffittNews today! Thank you to #TheReMissions and all our special guest singers who joined in for the fun. ❄️🎁🎄

Here’s our cover of “All I Want for Christmas is You!”
5
7
38
2,109
BioFlorida retweeted
Cyclo Therapeutics, Inc.@Cyclodexpert
7 Dec 2023
#NiemannPick Disease Type C is a rare, fatal and progressive genetic disorder characterized by a defect in the #NPC1 protein.

Learn more: bit.ly/3xg1ig8 $CYTH
0
2
5
231
BioFlorida retweeted
Alzheimer's Association
@alzassociation
5 Dec 2023
Abstract submissions for #AAIC24 are open! Submit your work for the chance to present at the most influential international meeting dedicated to advancing dementia science. Submissions due by Jan. 22, 2024. Learn more: alz.org/AAIC
1
12
34
3,580
Load more